Try our mobile app

TG Therapeutics Announces Positive Topline Results from the UNITY-CLL Phase 3 Study Evaluating the Combination of Umbralisib and Ublituximab (U2) for the Treatment of Patients with Chronic Lymphocytic Leukemia

Published: 2020-05-05 11:00:00 ET
<<<  go to TGTX company page

UNITY-CLL trial met the primary endpoint of improved progression-free survival (PFS) (p